JP2015523996A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523996A5 JP2015523996A5 JP2015518468A JP2015518468A JP2015523996A5 JP 2015523996 A5 JP2015523996 A5 JP 2015523996A5 JP 2015518468 A JP2015518468 A JP 2015518468A JP 2015518468 A JP2015518468 A JP 2015518468A JP 2015523996 A5 JP2015523996 A5 JP 2015523996A5
- Authority
- JP
- Japan
- Prior art keywords
- ylamino
- alkyl
- picolinamide
- tautomer
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 108
- 150000001875 compounds Chemical class 0.000 claims description 94
- 150000003839 salts Chemical class 0.000 claims description 79
- 125000005843 halogen group Chemical group 0.000 claims description 58
- 229910052757 nitrogen Inorganic materials 0.000 claims description 47
- -1 2-aminocyclohexyl Chemical group 0.000 claims description 45
- 125000005842 heteroatom Chemical group 0.000 claims description 44
- 125000000623 heterocyclic group Chemical group 0.000 claims description 43
- 229910052760 oxygen Inorganic materials 0.000 claims description 42
- 229910052717 sulfur Inorganic materials 0.000 claims description 42
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 24
- 125000002950 monocyclic group Chemical group 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 22
- 125000003342 alkenyl group Chemical group 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000028622 Immune thrombocytopenia Diseases 0.000 claims description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical group C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 102000000551 Syk Kinase Human genes 0.000 claims description 4
- 108010016672 Syk Kinase Proteins 0.000 claims description 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- OTLJSORUAVYKCM-QMTHXVAHSA-N 5-[[(1r,2r)-2-amino-3,3-difluorocyclohexyl]amino]-3-[(3-methyl-1,2-thiazol-5-yl)amino]pyridine-2-carboxamide Chemical compound S1N=C(C)C=C1NC1=CC(N[C@H]2[C@H](C(F)(F)CCC2)N)=CN=C1C(N)=O OTLJSORUAVYKCM-QMTHXVAHSA-N 0.000 claims description 2
- ILVFNIGLUOQZFL-AUUYWEPGSA-N 5-[[(1r,2r)-2-amino-3,3-difluorocyclohexyl]amino]-3-[(3-phenyl-1,2-oxazol-5-yl)amino]pyridine-2-carboxamide Chemical compound C1CCC(F)(F)[C@H](N)[C@@H]1NC1=CN=C(C(N)=O)C(NC=2ON=C(C=2)C=2C=CC=CC=2)=C1 ILVFNIGLUOQZFL-AUUYWEPGSA-N 0.000 claims description 2
- XJUWFPGPJSFMKA-ZWKOTPCHSA-N 5-[[(1r,2s)-2-aminocyclohexyl]amino]-3-(isoquinolin-6-ylamino)pyridine-2-carboxamide Chemical compound N[C@H]1CCCC[C@H]1NC1=CN=C(C(N)=O)C(NC=2C=C3C=CN=CC3=CC=2)=C1 XJUWFPGPJSFMKA-ZWKOTPCHSA-N 0.000 claims description 2
- GIPVWUDYOWOMIC-ZWKOTPCHSA-N 5-[[(1r,2s)-2-aminocyclohexyl]amino]-3-(isoquinolin-7-ylamino)pyridine-2-carboxamide Chemical compound N[C@H]1CCCC[C@H]1NC1=CN=C(C(N)=O)C(NC=2C=C3C=NC=CC3=CC=2)=C1 GIPVWUDYOWOMIC-ZWKOTPCHSA-N 0.000 claims description 2
- ZAHFUSJPHALHOW-FUHWJXTLSA-N 5-[[(1r,2s)-2-aminocyclohexyl]amino]-3-(quinolin-3-ylamino)pyridine-2-carboxamide Chemical compound N[C@H]1CCCC[C@H]1NC1=CN=C(C(N)=O)C(NC=2C=C3C=CC=CC3=NC=2)=C1 ZAHFUSJPHALHOW-FUHWJXTLSA-N 0.000 claims description 2
- ZZSHVZDSWOELCI-DLBZAZTESA-N 5-[[(1r,2s)-2-aminocyclohexyl]amino]-3-(quinolin-7-ylamino)pyridine-2-carboxamide Chemical compound N[C@H]1CCCC[C@H]1NC1=CN=C(C(N)=O)C(NC=2C=C3N=CC=CC3=CC=2)=C1 ZZSHVZDSWOELCI-DLBZAZTESA-N 0.000 claims description 2
- QHBQHOHSLDETLQ-QWHCGFSZSA-N 5-[[(1r,2s)-2-aminocyclohexyl]amino]-3-[(1-methylpyrazol-4-yl)amino]pyridine-2-carboxamide Chemical compound C1=NN(C)C=C1NC1=CC(N[C@H]2[C@H](CCCC2)N)=CN=C1C(N)=O QHBQHOHSLDETLQ-QWHCGFSZSA-N 0.000 claims description 2
- OPQCLRKBSMLBSY-NWDGAFQWSA-N 5-[[(1r,2s)-2-aminocyclohexyl]amino]-3-[(3-methyl-1,2-oxazol-5-yl)amino]pyridine-2-carboxamide Chemical compound O1N=C(C)C=C1NC1=CC(N[C@H]2[C@H](CCCC2)N)=CN=C1C(N)=O OPQCLRKBSMLBSY-NWDGAFQWSA-N 0.000 claims description 2
- RCHXGVBYMSHAQS-NWDGAFQWSA-N 5-[[(1r,2s)-2-aminocyclohexyl]amino]-3-[(3-methyl-1,2-thiazol-5-yl)amino]pyridine-2-carboxamide Chemical compound S1N=C(C)C=C1NC1=CC(N[C@H]2[C@H](CCCC2)N)=CN=C1C(N)=O RCHXGVBYMSHAQS-NWDGAFQWSA-N 0.000 claims description 2
- MGBHIZVOIJOKHN-JKSUJKDBSA-N 5-[[(1r,2s)-2-aminocyclohexyl]amino]-3-[(3-phenyl-1,2-oxazol-5-yl)amino]pyridine-2-carboxamide Chemical compound N[C@H]1CCCC[C@H]1NC1=CN=C(C(N)=O)C(NC=2ON=C(C=2)C=2C=CC=CC=2)=C1 MGBHIZVOIJOKHN-JKSUJKDBSA-N 0.000 claims description 2
- TUIJGSWIBLLOMH-DLBZAZTESA-N 5-[[(1r,2s)-2-aminocyclohexyl]amino]-3-[3-(triazol-2-yl)anilino]pyridine-2-carboxamide Chemical compound N[C@H]1CCCC[C@H]1NC1=CN=C(C(N)=O)C(NC=2C=C(C=CC=2)N2N=CC=N2)=C1 TUIJGSWIBLLOMH-DLBZAZTESA-N 0.000 claims description 2
- VKZQPQCNFHZOQT-SECBINFHSA-N 5-[[(2r)-1-amino-1-oxobutan-2-yl]amino]-3-[(3-methyl-1,2-thiazol-5-yl)amino]pyridine-2-carboxamide Chemical compound CC[C@H](C(N)=O)NC1=CN=C(C(N)=O)C(NC=2SN=C(C)C=2)=C1 VKZQPQCNFHZOQT-SECBINFHSA-N 0.000 claims description 2
- RTDMAPFXKCDGPZ-OAHLLOKOSA-N 5-[[(2r)-1-amino-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-[(3-methyl-1,2-thiazol-5-yl)amino]pyridine-2-carboxamide Chemical compound S1N=C(C)C=C1NC1=CC(N[C@H](CC2CCCCC2)C(N)=O)=CN=C1C(N)=O RTDMAPFXKCDGPZ-OAHLLOKOSA-N 0.000 claims description 2
- GBOLLXIGUKLNJY-GFCCVEGCSA-N 5-[[(2r)-1-amino-3-cyclopropyl-1-oxopropan-2-yl]amino]-3-[(3-methyl-1,2-thiazol-5-yl)amino]pyridine-2-carboxamide Chemical compound S1N=C(C)C=C1NC1=CC(N[C@H](CC2CC2)C(N)=O)=CN=C1C(N)=O GBOLLXIGUKLNJY-GFCCVEGCSA-N 0.000 claims description 2
- JIYFGMWHXSQZIW-GFCCVEGCSA-N 5-[[(2r)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-3-[(3-methyl-1,2-thiazol-5-yl)amino]pyridine-2-carboxamide Chemical compound CC(C)[C@H](C(N)=O)NC1=CN=C(C(N)=O)C(NC=2SN=C(C)C=2)=C1 JIYFGMWHXSQZIW-GFCCVEGCSA-N 0.000 claims description 2
- MOXZMMMJEZODAC-GOSISDBHSA-N 5-[[(2r)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-3-(isoquinolin-6-ylamino)pyridine-2-carboxamide Chemical compound CC(C)C[C@H](C(N)=O)NC1=CN=C(C(N)=O)C(NC=2C=C3C=CN=CC3=CC=2)=C1 MOXZMMMJEZODAC-GOSISDBHSA-N 0.000 claims description 2
- WUVPDZVGNHLOFF-GOSISDBHSA-N 5-[[(2r)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-3-(quinolin-6-ylamino)pyridine-2-carboxamide Chemical compound CC(C)C[C@H](C(N)=O)NC1=CN=C(C(N)=O)C(NC=2C=C3C=CC=NC3=CC=2)=C1 WUVPDZVGNHLOFF-GOSISDBHSA-N 0.000 claims description 2
- SKJLGEHBLIREKZ-GFCCVEGCSA-N 5-[[(2r)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-3-[(3-methyl-1,2-thiazol-5-yl)amino]pyridine-2-carboxamide Chemical compound CC(C)C[C@H](C(N)=O)NC1=CN=C(C(N)=O)C(NC=2SN=C(C)C=2)=C1 SKJLGEHBLIREKZ-GFCCVEGCSA-N 0.000 claims description 2
- UOTLABFUTQVVRM-QGZVFWFLSA-N 5-[[(2r)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-3-[(3-phenyl-1,2-oxazol-5-yl)amino]pyridine-2-carboxamide Chemical compound CC(C)C[C@H](C(N)=O)NC1=CN=C(C(N)=O)C(NC=2ON=C(C=2)C=2C=CC=CC=2)=C1 UOTLABFUTQVVRM-QGZVFWFLSA-N 0.000 claims description 2
- GINTYTKZGRBSLO-WDEREUQCSA-N 5-[[(3r,4r)-3-aminooxan-4-yl]amino]-3-[(3-methyl-1,2-thiazol-5-yl)amino]pyridine-2-carboxamide Chemical compound S1N=C(C)C=C1NC1=CC(N[C@H]2[C@H](COCC2)N)=CN=C1C(N)=O GINTYTKZGRBSLO-WDEREUQCSA-N 0.000 claims description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
- 206010002388 Angina unstable Diseases 0.000 claims description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 102000042838 JAK family Human genes 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 208000007814 Unstable Angina Diseases 0.000 claims description 2
- 208000035868 Vascular inflammations Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000028208 end stage renal disease Diseases 0.000 claims description 2
- 201000000523 end stage renal failure Diseases 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 208000007475 hemolytic anemia Diseases 0.000 claims description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 1
- 0 Cc1cccc2c1N=C*2 Chemical compound Cc1cccc2c1N=C*2 0.000 description 9
- 238000000034 method Methods 0.000 description 6
- XDDASCKVGFFJJS-DLBZAZTESA-N 5-[[(1r,2s)-2-aminocyclohexyl]amino]-3-[3-(1,3-oxazol-2-yl)anilino]pyridine-2-carboxamide Chemical compound N[C@H]1CCCC[C@H]1NC1=CN=C(C(N)=O)C(NC=2C=C(C=CC=2)C=2OC=CN=2)=C1 XDDASCKVGFFJJS-DLBZAZTESA-N 0.000 description 1
- YAHMLHDRILVVGU-UHFFFAOYSA-N CC(C)Cc1c[o]nc1 Chemical compound CC(C)Cc1c[o]nc1 YAHMLHDRILVVGU-UHFFFAOYSA-N 0.000 description 1
- GUCKIHDYYQOYJB-UHFFFAOYSA-N CC(C)c1cnc[s]1 Chemical compound CC(C)c1cnc[s]1 GUCKIHDYYQOYJB-UHFFFAOYSA-N 0.000 description 1
- GLCKJPGBFJELMD-UHFFFAOYSA-N CC1c(cccc2)c2NC=C1C Chemical compound CC1c(cccc2)c2NC=C1C GLCKJPGBFJELMD-UHFFFAOYSA-N 0.000 description 1
- QXGRNBYGFDGANB-UHFFFAOYSA-N CC[IH]1=CC=C2N1C=CC(C)=C2 Chemical compound CC[IH]1=CC=C2N1C=CC(C)=C2 QXGRNBYGFDGANB-UHFFFAOYSA-N 0.000 description 1
- WGRRBPXKOSKCJO-UHFFFAOYSA-N Cc(cc1)nc2c1[nH]cc2 Chemical compound Cc(cc1)nc2c1[nH]cc2 WGRRBPXKOSKCJO-UHFFFAOYSA-N 0.000 description 1
- KEBIZMQVCXHCGN-UHFFFAOYSA-N Cc1c(cc[nH]2)c2ncc1 Chemical compound Cc1c(cc[nH]2)c2ncc1 KEBIZMQVCXHCGN-UHFFFAOYSA-N 0.000 description 1
- HMXZIJABHDJYQQ-UHFFFAOYSA-N Cc1c2[nH]ccc2ncc1 Chemical compound Cc1c2[nH]ccc2ncc1 HMXZIJABHDJYQQ-UHFFFAOYSA-N 0.000 description 1
- PKZDPOGLGBWEGP-UHFFFAOYSA-N Cc1c[nH]c2ncccc12 Chemical compound Cc1c[nH]c2ncccc12 PKZDPOGLGBWEGP-UHFFFAOYSA-N 0.000 description 1
- QMHIMXFNBOYPND-UHFFFAOYSA-N Cc1c[s]cn1 Chemical compound Cc1c[s]cn1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 description 1
- DJCJHFFRHKGOCQ-UHFFFAOYSA-N Cc1cc(cc[nH]2)c2nc1 Chemical compound Cc1cc(cc[nH]2)c2nc1 DJCJHFFRHKGOCQ-UHFFFAOYSA-N 0.000 description 1
- XDHFUUVUHNOJEW-UHFFFAOYSA-N Cc1cc2cccnc2[nH]1 Chemical compound Cc1cc2cccnc2[nH]1 XDHFUUVUHNOJEW-UHFFFAOYSA-N 0.000 description 1
- IUICQPBDXPOULD-UHFFFAOYSA-N Cc1ccc[n]2nccc12 Chemical compound Cc1ccc[n]2nccc12 IUICQPBDXPOULD-UHFFFAOYSA-N 0.000 description 1
- WWDGTWAATSJUIM-UHFFFAOYSA-N Cc1cccc2ccn[n]12 Chemical compound Cc1cccc2ccn[n]12 WWDGTWAATSJUIM-UHFFFAOYSA-N 0.000 description 1
- AGQOIYCTCOEHGR-UHFFFAOYSA-N Cc1ccn[o]1 Chemical compound Cc1ccn[o]1 AGQOIYCTCOEHGR-UHFFFAOYSA-N 0.000 description 1
- LBBKWEDRPDGXPM-UHFFFAOYSA-N Cc1ccn[s]1 Chemical compound Cc1ccn[s]1 LBBKWEDRPDGXPM-UHFFFAOYSA-N 0.000 description 1
- JMFRWFPPCICJCQ-UHFFFAOYSA-N Cc1cnc(cc[nH]2)c2c1 Chemical compound Cc1cnc(cc[nH]2)c2c1 JMFRWFPPCICJCQ-UHFFFAOYSA-N 0.000 description 1
- DFYLLKBBGKQNMR-UHFFFAOYSA-N Cc1n[n](cccc2)c2c1 Chemical compound Cc1n[n](cccc2)c2c1 DFYLLKBBGKQNMR-UHFFFAOYSA-N 0.000 description 1
- CUMCMYMKECWGHO-UHFFFAOYSA-N Cc1n[o]cc1 Chemical compound Cc1n[o]cc1 CUMCMYMKECWGHO-UHFFFAOYSA-N 0.000 description 1
- WOTIUKDGJBXFLG-UHFFFAOYSA-N Cc1n[s]cc1 Chemical compound Cc1n[s]cc1 WOTIUKDGJBXFLG-UHFFFAOYSA-N 0.000 description 1
- YQDMUZFABFBKJN-UHFFFAOYSA-N Cc1nc([nH]cc2)c2cc1 Chemical compound Cc1nc([nH]cc2)c2cc1 YQDMUZFABFBKJN-UHFFFAOYSA-N 0.000 description 1
- VZWOXDYRBDIHMA-UHFFFAOYSA-N Cc1ncc[s]1 Chemical compound Cc1ncc[s]1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261663510P | 2012-06-22 | 2012-06-22 | |
| US61/663,510 | 2012-06-22 | ||
| US13/841,867 US20140113931A1 (en) | 2012-06-22 | 2013-03-15 | Substituted picolinamide kinase inhibitors |
| US13/841,867 | 2013-03-15 | ||
| PCT/US2013/045987 WO2013192046A2 (en) | 2012-06-22 | 2013-06-14 | Substituted picolinamide kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015523996A JP2015523996A (ja) | 2015-08-20 |
| JP2015523996A5 true JP2015523996A5 (OSRAM) | 2016-08-04 |
Family
ID=49769665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015518468A Pending JP2015523996A (ja) | 2012-06-22 | 2013-06-14 | 置換ピコリンアミドキナーゼ阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20140113931A1 (OSRAM) |
| EP (1) | EP2863905A4 (OSRAM) |
| JP (1) | JP2015523996A (OSRAM) |
| CN (1) | CN104602681A (OSRAM) |
| AU (1) | AU2013277473A1 (OSRAM) |
| CA (1) | CA2877469A1 (OSRAM) |
| HK (1) | HK1209316A1 (OSRAM) |
| IL (1) | IL235935A0 (OSRAM) |
| SG (1) | SG11201408074VA (OSRAM) |
| WO (1) | WO2013192046A2 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3077388A1 (en) | 2013-12-05 | 2016-10-12 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase |
| MA42623A (fr) * | 2015-06-02 | 2018-06-20 | Pharmacyclics Llc | Inhibiteurs de la tyrosine kinase de bruton |
| CA3122354A1 (en) | 2018-12-17 | 2020-06-25 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5107900A (en) * | 1999-06-09 | 2000-12-28 | Yamanouchi Pharmaceutical Co., Ltd. | Novel heterocyclic carboxamide derivatives |
| KR20100132550A (ko) * | 2008-04-16 | 2010-12-17 | 포톨라 파마슈티컬스, 인코포레이티드 | ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드 |
| ES2632220T3 (es) * | 2009-06-15 | 2017-09-11 | Rigel Pharmaceuticals, Inc. | Inhibidores de moléculas pequeñas de tirosina cinasa del bazo (SYK) |
| CA2816219C (en) * | 2010-11-01 | 2019-10-29 | Portola Pharmaceuticals, Inc. | Nicotinamides as syk modulators |
| EP2665711A1 (en) * | 2011-01-21 | 2013-11-27 | Abbvie Inc. | Picolinamide inhibitors of kinases |
| EP2763976B1 (en) * | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| WO2014153280A1 (en) * | 2013-03-22 | 2014-09-25 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
-
2013
- 2013-03-15 US US13/841,867 patent/US20140113931A1/en not_active Abandoned
- 2013-06-14 EP EP13807089.1A patent/EP2863905A4/en not_active Withdrawn
- 2013-06-14 SG SG11201408074VA patent/SG11201408074VA/en unknown
- 2013-06-14 CN CN201380042757.0A patent/CN104602681A/zh active Pending
- 2013-06-14 AU AU2013277473A patent/AU2013277473A1/en not_active Abandoned
- 2013-06-14 JP JP2015518468A patent/JP2015523996A/ja active Pending
- 2013-06-14 CA CA2877469A patent/CA2877469A1/en not_active Abandoned
- 2013-06-14 WO PCT/US2013/045987 patent/WO2013192046A2/en not_active Ceased
- 2013-06-14 HK HK15109941.4A patent/HK1209316A1/xx unknown
-
2014
- 2014-11-27 IL IL235935A patent/IL235935A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015520232A5 (OSRAM) | ||
| AU2021236451B2 (en) | P2X7 modulators | |
| JP7411631B2 (ja) | インターロイキン－１活性の阻害剤としてのスルホニル尿素化合物 | |
| CA2915129C (en) | Phosphatidylinositol 3-kinase inhibitors | |
| EP1326856B1 (en) | Pyridine derivatives with ikb-kinase (ikk-beta) inhibiting activity | |
| AU2001295026B2 (en) | Inhibitors of glycogen synthase kinase 3 | |
| EP3851107B1 (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| EP2970287B1 (en) | P2x7 modulators | |
| JP2011503193A5 (OSRAM) | ||
| JP2021518436A (ja) | Ｃｔｐｓ１阻害剤としてのアミノピリミジン誘導体 | |
| HK1250014A1 (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| JP2017149769A5 (OSRAM) | ||
| CA2599124A1 (en) | Imidazo (1,2-a) pyridine compounds as vegf-r2 inhibitors | |
| JP2013515729A5 (OSRAM) | ||
| CA2764728A1 (en) | Janus kinase inhibitor compounds and methods | |
| JP7821808B2 (ja) | がんの治療のための二環式テトラヒドロアゼピン誘導体 | |
| JP2018522823A5 (OSRAM) | ||
| AU2005245386A1 (en) | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer | |
| SI3087075T1 (en) | SYK INHIBITORS | |
| JP2021500340A5 (OSRAM) | ||
| KR102960345B1 (ko) | Irak4 억제제로서 유용한 트리시클릭 헤테로아릴 화합물 | |
| JP2016540803A5 (OSRAM) | ||
| JP2015520232A (ja) | １，２，４−トリアジン−６−カルボキサミドキナーゼ阻害剤 | |
| JP2019532914A (ja) | 選択的ｊａｋ阻害剤としての化合物、該化合物の塩類および治療への使用 | |
| RU2015107426A (ru) | Пирроло[2,3-в]пиразины в качестве ингибиторов syk |